Cognition Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Cognition Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.000.000.000.000.00
Gross Profit0.000.000.000.000.00
Operating Expenses
Research & Development41.6837.2030.3218.5712.89
Selling, General & Administrative12.2913.5313.2310.034.52
Operating Expenses53.9750.7221.3311.1517.41
Operating Income-53.97-50.72-21.33-11.15-17.41
Other Income/Expense
Interest Income0.000.000.000.000.00
Interest Expense-0.03-0.030.030.89-1.75
Other Income/Expense20.2224.96-0.040.3311.45
Income
Income Before Tax-33.97-25.79-21.40-11.72-7.84
Income Tax Expense0.000.000.000.000.00
Net Income-33.97-25.79-21.40-11.72-7.84
Net Income - Continuous Operations-33.97-25.79-21.40-11.720.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-53.86-50.63-21.13-10.73-17.31
EBIT-53.97-50.72-21.37-10.82-17.41
Depreciation & Amortization0.110.100.240.090.10
Earnings Per Share
Basic EPS-1.00-1.00-1.00-3.00-24.00
Diluted EPS-1.00-1.00-1.00-3.00-24.00
Basic Shares Outstanding39.7330.0323.645.190.51
Diluted Shares Outstanding39.7330.0323.645.190.51